Wall Street analyst estimates for Dermata Therapeutics, Inc. (DRMA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 1.30 |
| EV / EBITDA | 0.42 |
| Dividend Yield | 0.00% |
Price
| Price | $1.15 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTL · ATXI · CARM · ELAB · GTBP · LIPO · PBM
Explore sector: Healthcare · Biotechnology
More sections of DRMA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks